Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-04-04
2009-11-03
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S278000
Reexamination Certificate
active
07612056
ABSTRACT:
This invention concerns substituted diaza-spiro-[4.5]-decane derivatives having neurokinin antagonistic activity, in particular NK1antagonistic activity, a combined NK1/NK2antagonistic activity, a combined NK1/NK3antagonistic activity and a combined NK1/NK2/NK3antagonistic activity, their preparation, compositions comprising them and their use as a medicine, in particular for the treatment and/or prophylaxis of schizophrenia, emesis, anxiety and depression, irritable bowel syndrome (IBS), circadian rhythm disturbances, pre-eclampsia, nociception, pain, in particular visceral and neuropathic pain, pancreatitis, neurogenic inflammation, asthma, chronic obstructive pulmonary disease (COPD) and micturition disorders such as urinary incontinence.The compounds according to the invention can be represented by general Formula (I)and comprises also the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof, the N-oxide form thereof and prodrugs thereof, wherein all substituents are defined as in Claim1.
REFERENCES:
patent: 5861416 (1999-01-01), Burkholder et al.
patent: 5869496 (1999-02-01), Hale et al.
patent: 6167773 (2001-01-01), Dorfschmid et al.
patent: 6169097 (2001-01-01), Janssens et al.
patent: 7288548 (2007-10-01), Chan Chun Kong et al.
patent: 2002/0006932 (2002-01-01), Galley et al.
patent: 2004/0096798 (2004-05-01), Cleary
patent: 2 142 332 (1985-01-01), None
patent: 11 043435 (1999-02-01), None
patent: WO 97/24324 (1997-07-01), None
patent: WO 97/24350 (1997-07-01), None
patent: WO 97/24356 (1997-07-01), None
patent: WO 99/32489 (1999-07-01), None
patent: WO 01/94346 (2001-12-01), None
Aguiar and Brandao, Physiol. Behav. 60:1183-1186 (1996).
Ballard et al., Inhibition of shock-induced foot tapping behavious in the gerbil by a tachykinin NK1 receptor antagonist; European Journal of Pharmacology (2001), 412(3), pp. 255-264.
Bertrand and Geppetti, Trends Pharmacol. Sci. 17:255-259 (1996).
Brodin et al., Neuropeptides 26:253-260 (1994).
Campos et al., J. Clin. Oncol. 19:1759-1767 (2001).
Cocquyt et al., Eur. J. Cancer 37:835-842 (2001).
Culman and Unger, Can. J. Physiol. Pharmacol. 73:885-891 (1995).
De Mulder et al., Annuals of Internal Medicine 113:834-840 (1990).
Drugs, 1985, 29, pp. 455-473.
Elliott, Exp. Brain. Res. 73:354-356 (1988).
Gaudreau & Ploudre, Neurosci. Lett. 351:59-62 (2003).
Giardina, G. et al. Exp. Opin. Ther. Patents, 10(6): 939-960 (2000).
Goldstein et al., Clin. Pharm. Ther. 67:419-426 (2000).
Hesketh et al., Clin. Oncol. 17:338-343 (1999).
Hesketh et al., J. Clin. Oncol. 15:103 (1997).
International search report of the PCT/EP2004/050458.
J. Am. Chem. Soc. 1998, 120,11798-11799.
J. Org. Chem, 1990, 55, 2552-2554.
Julia et al., Gastroenterol. 116:1124-1131 (1999).
Kamp et al., J. Pharmacol. Exp. Ther.299:105-113 (2001).
Kramer et al., Science 281:1640-1645 (1998).
Krase et al., Behav. Brain. Res. 63:81-88 (1994).
Kris et al., J. Clin. Oncol., 3:1379-1384 (1985).
Lejeune et al.; The selective neurokinin (NK)1 antagonist, GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a combined dialysis and electrophysiological study; Brain Research, (2002), 935(1,2), pp. 134-139.
Longmore J. et al., DN&P 8(1):5-23 (1995).
Lundberg, Can. J. Physiol. Pharmacol. 73:908-914 (1995).
Maggi and Schwartz, Trends Pharmacol. Sci. 18: 351-355 (1997).
Maggi, Gen. Pharmacol. 26:911-944 (1995).
Megens et al., J. Pharmacol. Exp. Ther. 302:696-709 (2002).
Meltzer Herbert Y et al; Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder; The American journal of psychiatry; (2004), 161(6), pp. 975-984.
Navari et al., N. Engl. L. Med. 340:190-195 (1999).
Naylor and Rudd, Cancer. Surv. 21:117-135 (1996).
Okano et al., J. Pharmacol. Exp. Ther. 298:559-564 (2001).
Piedimonte et al., L. Pharmacol. Exp. Ther. 266:270-273 (1993).
Regoli et al., Pharmacol. Rev. 46(4):551-599 (1994).
Roila, Oncology 50:163-167 (1993).
Rudd and Naylor, Neuropharmacology 33:1607-1608 (1994).
Rudd et al., Br. J. Pharmacol. 119:931-936 (1994).
Rupniak and Kramer, Trends Pharmacol. Sci. 20:1-12 (1999).
Sam et al., Eur. J. Pharmacol. 417:231-237 (2001).
Shirayama et al., Brain. Res. 739:70-78 (1996).
Stella, V. J. et al., “Prodrugs”, Drug Delivery Systems, 1985, pp. 112-176.
Tattersall et al., Neuropharmacol. 35:1121-1129 (1996).
Tattersall et al., Neuropharmacology 39:652-663 (2000).
Teixeira et al., Eur. J. Pharmacol. 311:7-14 (1996).
Tetrahedron Letters, 2002, 43, 5965-5968.
Tetrahedron, 1997, 53, 16463-16470.
Textbook of Organic Medicinal and Pharmaceutical Chemistry, 1977, pp. 70-75.
Tonini el al., Gastroenterol. 120:938-945 (2001).
Watson et al., Br. J. Pharmacol. 115:84-94 (1995).
Poulsen, A. et al; “A pharmacophore model for NK2 antagonist comprising compounds from several structurally diverse classes;” Journal of Computer-Aided Molecular Design; 2002, 16:4; pp. 273-286.
Harrison, T. et al.; “High Affinity, Selective Neurokinin 2 and Neurokinin 3 Receptor Antagonists from a Common Structural Template;” Bioorganic & Medicinal Letters; 8 (1998); pp. 1343-1348.
Coupa Sophie
Janssens Frans Eduard
Poncelet Alain Philippe
Schoentjes Bruno
Simonnet Yvan René Ferdinand
Jenssen Pharmaceutica N.V.
Krass Frederick
Sznaidman Marcos
Woodcock & Washburn LLP
LandOfFree
Substituted diaza-spiro-[4.5]-decane derivatives and their... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted diaza-spiro-[4.5]-decane derivatives and their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted diaza-spiro-[4.5]-decane derivatives and their... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4141817